Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published in ...

Source: Getty Images Enfortumab vedotin produced a response in 23.9% of patients. One patient achieved a complete response, and 10 had a partial response. Enfortumab vedotin may be a treatment option ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Padcev (enfortumab vedotin-ejfv) is a brand-name infusion prescribed for urothelial cancer (a type of bladder cancer). As with other drugs, Padcev can cause side effects, such as rash and hair loss.

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV ™ (enfortumab vedotin, an antibody-drug conjugate ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Enter Seattle Genetics and Astellas, who are jointly developing enfortumab vedotin, an antibody-drug conjugate intended as an option for patients whose disease has progressed despite treatment ...

Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice This open-label, ...

Astellas Pharma Inc., a pharmaceutical company conducting business in more than 70 countries around the world, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Padcev ...

Enfortumab vedotin (EV) is the first drug in this new class to be approved by the EMA at for the treatment of patients and patients with metastatic urothelial carcinoma. Given the extremely ...

And then in patients who are receiving chemotherapy followed by maintenance avelumab [Bavencio], after that some patients are receiving enfortumab vedotin [EV, Padcev], and then after that ...